Novavax, Inc. has announced preclinical data for its H5N1 avian pandemic influenza vaccine candidate, which demonstrated immunogenicity against currently circulating variants. The study, published in Nature Communications, showed that the vaccine, which utilizes Novavax's recombinant, protein-based nanoparticle technology and Matrix-M® adjuvant, induced robust immune responses in nonhuman primates following either a single or two-dose administration via intranasal or intramuscular routes. The results indicated that even a single dose could potentially provide protective immunity, especially in individuals previously exposed to seasonal influenza. These findings suggest that Novavax's vaccine could play a significant role in pandemic emergency preparedness efforts. The company is seeking funding, partnership, and licensing opportunities to advance its H5N1 vaccine candidate.